What documented beneficial effects have been observed with intravenous nicotinamide adenine dinucleotide (NAD) infusion?

Documented Beneficial Effects of NAD Infusion

The evidence for beneficial effects of intravenous NAD infusion in humans is extremely limited and consists primarily of one small randomized trial showing improved cardiac function in heart failure patients, while mechanistic data suggests potential benefits through cellular energy metabolism and DNA repair pathways.

Evidence from Human Clinical Trials

Cardiac Function in Heart Failure

The most robust human evidence comes from a single-center randomized controlled trial in ischemic cardiomyopathy patients 1. This study demonstrated:

• Improved left ventricular ejection fraction (LVEF): Patients receiving IV NAD+ (10 mg/day for 7 days) showed significantly greater LVEF improvement at 1 month compared to placebo (45.44% vs 42.44%, p=0.024)
• Trend toward reduced NT-proBNP levels at day 7, suggesting improved cardiac stress markers
• Trend toward fewer major adverse cardiac events at 6 months (14.6% vs 24.7%, p=0.089), primarily driven by reduced heart failure hospitalizations
• Improved functional capacity: Greater proportion showed NYHA functional class improvement at 1 month (73.0% vs 57.3%)

This represents the only documented mortality/morbidity outcome data for IV NAD in humans, though the study was relatively small (180 patients) and single-center.

Pharmacokinetic and Metabolic Observations

Rapid Clearance and Metabolism

A pilot pharmacokinetic study revealed important limitations 2:

• NAD+ is rapidly cleared from plasma during the first 2 hours of infusion at 3 μmol/min
• No increase in plasma NAD+ or metabolites occurred until after 2 hours of continuous infusion
• The metabolite profile suggests breakdown via NAD+ glycohydrolase and pyrophosphatase activity
• Urinary excretion includes methylnicotinamide and NAD+ itself, but not nicotinamide

Critical caveat: This rapid clearance suggests that IV NAD may not effectively raise systemic NAD+ levels as intended, raising questions about the mechanism of any observed benefits.

Tolerability and Safety Profile

Significant Tolerability Issues

A retrospective comparison of NAD+ versus nicotinamide riboside (NR) infusions showed marked differences 3:

NAD+ IV (500 mg over 4 consecutive days):

• Moderate to severe gastrointestinal symptoms
• Increased heart rate and chest pressure during infusions
• Average infusion time of 97 minutes (due to symptom management)
• Significant decrease in HDL-cholesterol (clinical significance unclear)

Safety markers: No significant changes in liver enzymes (ALT, AST), inflammatory markers (hsCRP), renal function, or thyroid function over 30 days 3.

Mechanistic Rationale (Not Direct Evidence of Benefit)

The guidelines provide theoretical framework but not clinical evidence for IV NAD 4, 5:

Cellular Functions of NAD+

• Cofactor for >400 enzymes involved in energy metabolism 5
• DNA repair processes through PARP activation
• Mitochondrial function and ATP production
• Antioxidant effects and redox homeostasis

Age-Related Decline

• NAD+ levels decline significantly with aging in both animal models and humans 4
• This decline correlates with increased oxidative stress, DNA damage, and mitochondrial dysfunction
• However, these are associations, not evidence that IV NAD reverses these processes in humans

Critical Limitations and Caveats

Lack of Evidence for Common Claims

Important: The provided evidence does NOT support IV NAD infusion for:

• Anti-aging or longevity (no human data)
• Neurodegenerative diseases (no human data)
• Energy enhancement in healthy individuals (no data)
• Athletic performance (no data)
• Addiction treatment (no data)

Route of Administration Matters

The guidelines discuss niacin (vitamin B3) supplementation, which is the precursor to NAD+, not direct NAD+ infusion 5:

• Oral niacin/nicotinamide: 15-20 mg/day for pellagra treatment
• Parenteral nutrition: 40 mg/day recommended
• These doses are vastly different from commercial IV NAD protocols (often 250-1000 mg)

FDA Status

The FDA drug label provided 6 lists NAD as an inactive ingredient in a cosmetic dermatologic product, not as an active therapeutic agent for systemic administration.

Clinical Bottom Line

For heart failure due to ischemic cardiomyopathy: One small trial suggests potential benefit with 10 mg/day IV NAD for 7 days, showing improved LVEF and trends toward better clinical outcomes 1. This requires validation in larger multicenter trials.

For all other indications: There is insufficient human evidence to recommend IV NAD infusion. The rapid plasma clearance 2, significant tolerability issues 3, and lack of clinical outcome data make routine use premature outside of research protocols.

If considering use: Patients should be informed that evidence is extremely limited, tolerability may be poor requiring slow infusion rates, and the mechanism of any benefit remains unclear given the rapid clearance from plasma. The theoretical benefits based on NAD+ cellular functions have not been translated into documented clinical benefits for most proposed indications.